#soliris in india

[solirisinjection]

All About Soliris Injection

Soliris (eculizumab) is a complement inhibitor used to treat two rare and serious medical conditions. It is approved for patients with paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis and for patients with atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy. If you want to know about the Soliris price in India, it’s essential to know that the drug is currently available through legal import channels only, as it has not yet been approved by the Indian regulatory authority.

Soliris is supplied as an intravenous (IV) injection, with each vial containing 300 mg/30 mL (10 mg/mL) of the medicine. Its effectiveness in managing rare diseases like PNH and aHUS has made it a life-saving treatment for patients worldwide.

Accessing Soliris (eculizumab) in India: Eculizumab is not yet approved in India. Patients requiring Soliris (eculizumab) on an immediate basis can obtain it through a Named Patient Import Permit, a legal framework allowing individuals to access unapproved medications for personal use. The process ensures that Indian patients can procure Soliris safely and reliably.

How Does Soliris (eculizumab) Work? Soliris works by targeting and inhibiting the complement system, a part of the immune system that can mistakenly attack the body’s own cells in conditions like PNH and aHUS. By blocking this process, the drug reduces hemolysis (destruction of red blood cells), prevents blood clots, and protects organs from damage.

Side Effects of Soliris (eculizumab): While this therapeutic drug is highly effective, it may cause some side effects, including:

headache

nausea

fatigue

fever

upper respiratory tract infections

It is crucial to administer Soliris under strict medical supervision, and patients should be monitored for any adverse reactions.

Procure Soliris with Our Support: Patients in India who want to procure Soliris can rely on our expertise to navigate the complex process of legal import. Our team has a proven track record of helping Indian patients access advanced therapies like Eculizumab. We work with licensed global sources to ensure that this medicinal product is genuine and procured through authorized channels. From assisting with the Named Patient Import Permit application to coordinating with global suppliers, we provide end-to-end support for patients in need. For those who require Soliris injection, we can help simplify the process and ensure timely access to this life-saving treatment.

Reach Out to Us: Contact us today via Call/WhatsApp: +91 9310090915 to learn how you can buy Soliris online in India. Our dedicated team is here to support you every step of the way. We ensure you receive the best quality and advanced medicines.

What is Soliris, and how can I access it in India?

Soliris (eculizumab) is a complement inhibitor used to treat rare disorders like paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). As Soliris is not yet approved in India, it can only be accessed through a Named Patient Import Permit. This legal framework allows patients to import unapproved medications for personal use under medical supervision.

Can I buy Soliris in India, specifically in cities like Lucknow, Delhi, or Noida?

Yes, patients in India, including those in Lucknow, Delhi, Noida, Mumbai, Chennai, Hyderabad, Kolkata, Pune, and Ahmedabad, can legally procure Soliris through authorized channels. The process requires obtaining a Named Patient Import Permit and sourcing the medication from reliable global suppliers.

Is Soliris approved in India?

No, Soliris is not yet approved for commercial use in India. However, patients can still access the drug legally through the Named Patient Import process, which ensures the medication is imported for personal use under strict regulatory guidelines.

How can the Indian Pharma Network (IPN) help me buy Soliris in India?

Indian Pharma Network (IPN) assists patients in India with the legal import of Soliris. We guide Named Patient Import applications, source genuine medication from licensed global suppliers, and ensure timely delivery, provide reliable access to life-saving treatments.

How can I trust the authenticity of Soliris purchased through IPN?

IPN collaborates only with licensed and reputable global Soliris suppliers to ensure that all medications, including Soliris injections, are authentic and sourced through authorized channels. Our strong track record in facilitating drug imports for Indian patients guarantees a trustworthy and seamless process.

[kkumarsblog]

Guillain-Barré Syndrome (GBS) Market Overview

Guillain-Barré Syndrome (GBS) is a rare autoimmune disorder that affects the peripheral nervous system, often causing muscle weakness or paralysis. Typically triggered by infections or immune-related factors, GBS has gained significant attention due to rising awareness and the demand for effective treatments. Enhanced healthcare infrastructure and ongoing research have been key drivers of the market’s growth.

Guillain-Barré Syndrome Market Growth Trends and Influencers

The GBS market has experienced steady expansion, driven by advancements in diagnostic methods, increased healthcare investments, and greater awareness of rare conditions. North America leads the market, supported by its advanced healthcare systems, higher prevalence of autoimmune disorders, and substantial research funding. Meanwhile, Europe and the Asia-Pacific region are emerging as significant contributors, fueled by better healthcare access and supportive government initiatives.

Current Therapeutic Approaches

Existing treatments for GBS focus on managing symptoms, slowing disease progression, and supporting recovery. Key options include:

Plasma Exchange (Plasmapheresis): Removes harmful antibodies from the blood.

Intravenous Immunoglobulin (IVIG): Administers antibodies from healthy donors to counteract damaging immune responses.

Supportive Care: Includes physical therapy, respiratory assistance, and pain management to aid recovery.

Although these treatments are effective in symptom management, they do not offer a cure, emphasizing the need for more advanced solutions.

Innovative Therapies in Development

Research efforts are focused on developing novel therapies that target the immune system’s underlying mechanisms. Cutting-edge advancements such as monoclonal antibodies and immunomodulatory drugs are being explored to improve treatment efficacy and reduce side effects.

Key Market Drivers and Obstacles

Drivers of Growth:

Increased Awareness: Educational campaigns have improved early diagnosis and treatment outcomes.

Technological Innovations: Biotechnological advancements have enabled the development of precise, targeted therapies.

Rising Prevalence: Growing cases linked to post-infection complications, such as those caused by Zika virus and COVID-19, have heightened demand for treatment.

Challenges:

High Costs: Treatments like IVIG and plasmapheresis remain expensive, limiting their availability in lower-income regions.

Lack of a Cure: Current therapies manage symptoms but do not address the disease’s root cause.

Complex Pathophysiology: The intricate nature of GBS complicates drug development efforts.

Leading Companies in the GBS Drug Market

Key players driving innovation in the GBS market include:

Grifols and CSL Behring: Leading producers of IVIG therapies.

Octapharma: Innovators in plasma-derived treatments.

Biogen and Alexion Pharmaceuticals: Pioneers in developing monoclonal antibodies and complement inhibitors for autoimmune conditions.

Emerging Treatment Options

Noteworthy therapies currently under investigation include:

Eculizumab (Soliris): A complement inhibitor aimed at preventing immune-mediated nerve damage.

FcRn Inhibitors: Drugs designed to reduce harmful autoantibody levels, showing promise in early trials.

Neuroprotective Agents: Targeted therapies to protect nerve cells and promote regeneration.

Regional Market Insights

North America: Dominates the GBS market with its advanced healthcare infrastructure, high awareness levels, and significant research investments.

Europe: Growth is driven by supportive healthcare policies, reimbursement schemes, and robust systems in countries like Germany, France, and the UK.

Asia-Pacific: Rapid growth in emerging economies such as China and India is fueled by increasing healthcare investments and public awareness initiatives.

Latin America and the Middle East & Africa: These regions are gradually advancing through improved healthcare access and affordability.

Future Prospects for the GBS Market

The GBS market holds promising potential, with advancements in biotechnology and personalized medicine paving the way for transformative progress. Key trends shaping the future include:

Personalized Medicine: Customizing treatments based on individual genetic and immunological profiles.

Digital Health Integration: Leveraging telemedicine and wearable technology for enhanced monitoring and care.

Collaborative Efforts: Partnerships between pharmaceutical companies, research institutions, and governments to drive innovation.

Conclusion

The Guillain-Barré Syndrome market is evolving rapidly, supported by technological advancements, increased awareness, and collaborative initiatives. While challenges such as high treatment costs and the lack of a definitive cure persist, emerging therapies offer hope for better patient outcomes and higher standards of care.

Top Market Research Reports for 2024

Microscopy Device Market

Medical Marijuana Market

Asperger Syndrome Market

Penile Cancer Market

Total Knee Arthroplasty Market

Lactose Intolerance Market

Bone Growth Stimulators Market

Urea Cycle Disorders Market

Surgical Mask & Respirator Market

Dyspepsia Market

DelveInsight Consulting Services

CDMO Competitive Assessment in the USA and Europe: DelveInsight offers comprehensive analysis of the Contract Development and Manufacturing Organization (CDMO) sector, highlighting trends, market leaders, and competitive dynamics.

Competitive Benchmarking Services: DelveInsight’s benchmarking services provide actionable insights to help organizations effectively navigate the competitive healthcare and pharmaceutical markets.

About DelveInsight

DelveInsight is a leading market research and consulting firm specializing in healthcare and life sciences. It offers customized solutions and data-driven insights to support strategic decision-making.

Contact Information: Kanishk Kumar Email: kkumar@delveinsight.com

[oncologyadvice]

eculizumab price

Soliris Injection is used for the treatment of Blood Cancer and is manufactured by Alexion Pharmaceuticals. Strength of this medicine is 300mg. Composition of this medicine is Eculizumab.

Know more about eculizumab injection

Composition: Eculizumab

Manufacturer: Alexion     Pharmaceuticals

Indication: Blood     cancer

Packaging: Vial

Dosage Form: Injection

If you are looking for eculizumab price, then please visit Magicine Pharma. This medicine is available in Pakistan, Philippines, Egypt, India, Australia and UAE.

[palakjain123]

Global Myasthenia Gravis Treatment Market, Size, Share, Analysis &Industry Report to 2026

The global myasthenia gravis treatment market is anticipated to showcase considerable growth during the forecast period (2020-2026). The rising FDA approvals, advancement in new treatment therapies, new product launches, and improvement in surgical procedures are some of the key factors contributing to the growth of the global myasthenia gravis treatment market. Myasthenia gravis is a chronic autoimmune, neuromuscular disorder that leads to weakness in the skeletal muscles. Eyes, face, and swallowing are the most affected muscles. According to the National Center for Biotechnology Information (NCBI), 0.25 and 20 per 1,000,000 population have an annual incidence of myasthenia gravis.

Get Free Sample Copy @ https://www.omrglobal.com/request-sample/myasthenia-gravis-treatment-market

LEO Pharma A/S, Mylan N.V., Bausch Health Companies Inc., Bayer HealthCare AG, Encore Dermatology, Inc., Abbvie Inc., Allergan PLC, Bausch Health Companies Inc., Encore Dermatology Inc., GlaxoSmithKline PLC, Nestle SA, Novartis International AG, Pfizer Inc., and so on are among the key players operating in the global myasthenia gravis treatment market. Mergers and acquisitions, partnerships, collaboration, and strategic agreements among others are the key growth strategies that are being adopted by the major players operating in the market to remain competitive in the market place. Hefty investment in the R&D of new drugs for new product launches is the key strategy adopted by the key players of the global myasthenia gravis treatment market to sustain in the marketplace.

A Full Report of Global Myasthenia Gravis Treatment Marketis Available at:https://www.omrglobal.com/industry-reports/myasthenia-gravis-treatment-market

In November 2019, Amneal Pharmaceuticals, Inc. had signed a licensing agreement with KashivBioSciences LLC for the development and commercialization of K127 in the US. K127 is an extended-release tablet of pyridostigmine, for the treatment of myasthenia gravis which is used to offer rapid onset and 24-hour coverage for improved symptom control, better tolerability, better compliance, and quality of life to the myasthenia gravis patients. The commercialization of the product is anticipated to drive the growth of the myasthenia gravis treatment market in the US.  

In March 2019, Novartis AG had received FDA approval for Mayzent (siponimod) tablets, the first oral drug to treat the secondary progressive autoimmune disorder. In October 2017, Alexion Pharmaceuticals, Inc. had received the US FDA approval for Soliris (eculizumab) as a treatment for adult patients with generalized myasthenia gravis and are anti-acetylcholine receptor (AchR) antibody-positive. In Phase 3 REGAIN trial and its continuing open-label extension trial, Soliris showed therapeutic advantages for patients with anti-AchR antibody-positive who had previously failed immunosuppressive care and continued to experience severe symptoms of the unresolved disease, which could include problems seeing, walking, communicating, chewing, and respiratory.

Global Myasthenia Gravis Treatment Market Segmentation

By Treatment

Medication

o          Cholinesterase Inhibitors

o          Corticosteroids

o          Immunosuppressants

Surgery

Others

By End-User

Hospitals

Clinics

Other

Global Myasthenia Gravis Treatment Market – Segment by Region 

North America

United     States

 Canada

Europe

UK

Germany

Italy

Spain

France

Rest of     Europe

Asia-Pacific

China

Japan

 India

Rest of the     Asia-Pacific

Rest of the World

For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/myasthenia-gravis-treatment-market

About Orion Market Research

Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.

Media Contact: Company Name: Orion Market Research Contact Person: Mr. Anurag Tiwari Email: info@omrglobal.com  Contact no: +91 780-304-0404

[wiseguyreport1222]

At the beginning of 2020, COVID-19 disease began to spread around the world, millions of people worldwide were infected with COVID-19 disease, and major countries around the world have implemented foot prohibitions and work stoppage orders. Except for the medical supplies and life support products industries, most industries have been greatly impacted, and Soliris (Eculizumab) industries have also been greatly affected.

GET FREE SAMPLE PDF :https://www.wiseguyreports.com/sample-request/7301488-global-soliris-eculizumab-market-report-2021

This Report covers the manufacturers' data, including: shipment, price, revenue, gross profit, interview record, business distribution etc., these data help the consumer know about the competitors better. This report also covers all the regions and countries of the world, which shows a regional development status, including market size, volume and value, as well as price data. Besides, the report also covers segment data, including: type segment, industry segment, channel segment etc. cover different segment market size, both volume and value. Also cover different industries clients information, which is very important for the manufacturers. If you need more information, please contact BisReport

Section 1: Free----Definition

Section (2 3): 1200 USD----Manufacturer Detail Alexion

REPORT DETAILS:https://www.wiseguyreports.com/reports/7301488-global-soliris-eculizumab-market-report-2021

Section 4: 900 USD----Region Segmentation North America Country (United States, Canada) South America Asia Country (China, Japan, India, Korea) Europe Country (Germany, UK, France, Italy) Other Country (Middle East, Africa, GCC)

Section (5 6 7): 500 USD---- Product Type Segmentation Plasma Exchange Plasma Infusion

Industry Segmentation PNH aHUS

Channel (Direct Sales, Distributor) Segmentation

Section 8: 400 USD----Trend (2020-2025)

Section 9: 300 USD----Product Type Detail

Section 10: 700 USD----Downstream Consumer

Section 11: 200 USD----Cost Structure

Section 12: 500 USD----Conclusion

TABLE OF CONTENTS

Section 1 Soliris (Eculizumab) Product Definition

Section 2 Global Soliris (Eculizumab) Market Manufacturer Share and Market Overview 2.1 Global Manufacturer Soliris (Eculizumab) Shipments 2.2 Global Manufacturer Soliris (Eculizumab) Business Revenue 2.3 Global Soliris (Eculizumab) Market Overview 2.4 COVID-19 Impact on Soliris (Eculizumab) Industry

Section 3 Manufacturer Soliris (Eculizumab) Business Introduction 3.1 Alexion Soliris (Eculizumab) Business Introduction 3.1.1 Alexion Soliris (Eculizumab) Shipments, Price, Revenue and Gross profit 2015-2020 3.1.2 Alexion Soliris (Eculizumab) Business Distribution by Region 3.1.3 Alexion Interview Record 3.1.4 Alexion Soliris (Eculizumab) Business Profile 3.1.5 Alexion Soliris (Eculizumab) Product Specification

3.2.3 Interview Record

3.3.3 Interview Record

..... continued

CONTACT DETAILS :

sales@wiseguyreports.com

+44 203 500 2763

+1 62 825 80070

971 0503084105

[jesse-pinkman123]

Paroxysmal Nocturnal Hemoglobinuria Therapeutics Market Analysis - 2027

Global Paroxysmal Nocturnal Hemoglobinuria Therapeutics Market: Drivers

The global Paroxysmal Nocturnal Hemoglobinuria Therapeutics Market size is expected to witness significant growth over the forecast period, owing to increasing demand for PNH therapeutics and rising number of treatment approvals from the U.S. Food and Drug Administration (FDA) for PNH, which includes iron supplements, blood transfusion, blood thinner, Eculizumab (Soliris), and bone marrow transplant. According to a study published in Blood Journal in 2012, the 5 year survival-rate of patients treated with Soliris is 95.5%.

Moreover, new R&D studies are being conducted for development of cost-effective PNH treatment, which is expected to drive the paroxysmal nocturnal hemoglobinuria therapeutics market revenue. For instance, in 2014, the research team of Perelman School of Medicine at Pennsylvania, U.S. investigated a compound named PEG-Cp40, which is long-acting and cost-effective for the treatment of paroxysmal nocturnal hemoglobinuria.

The paroxysmal nocturnal hemoglobinuria (PNH) is a rare, acquired bone marrow failure disorder, which leads to premature death and impaired red blood cells (RBCs). PNH is characterized by hemolytic anemia, thrombosis, and peripheral blood cytopenia. Mutation in the PIGA-A gene of hematopoietic stem cells causes deficiency of the two glycosylphosphatidylinositol (GPI) anchored proteins, namely CD55 and CD59 in the patient’s body, which gives rise to the premature destruction of RBCs.

* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.

Request a sample copy of this report: https://www.coherentmarketinsights.com/insight/request-sample/2542

Symptoms of paroxysmal nocturnal hemoglobinuria includes hemolytic anemia, hemoglobinuria, fatigue, breathlessness, abdominal pain, difficulty in controlling bleeding even from very minor wounds, appearance of small red dots on the skin that indicates bleeding under the skin, severe headache, and blood clots (thrombosis). Bone marrow transplant (stem cell transplant) is the only curative therapy for paroxysmal nocturnal hemoglobinuria available so far.

Global Paroxysmal Nocturnal Hemoglobinuria Therapeutics Market: Restraints

The paroxysmal nocturnal hemoglobinuria therapeutics market revenue is expected to hamper because of high cost for the treatment of paroxysmal nocturnal hemoglobinuria. For instance, in 2017, the American Council on Science and Health (ACSH) declared Eculizumab (Soliris) as the most expensive drug in the U.S. and cost of Solirirs ranges up to US$ 500,000 per person per year.

Moreover, the side effects shown by the drug Soliris such as headache, fatigue, nausea, vomiting, diarrhea, muscle pain, and nasal congestion can also negatively impact the paroxysmal nocturnal hemoglobinuria therapeutics market size. There are some serious side effects also, which includes low White Blood Cell (WBC) count, increased chances of bacterial infections such as meningitis, and bacterial sinusitis. According to the Centers for Disease Control and Prevention (CDC) reports of 2017, patients under the therapy of Eculizumab (Soliris) are at 1,000 to 2,000 times greater at risk of getting meningococcal diseases han the healthy individuals in the U.S.

Browse Research Report: https://www.coherentmarketinsights.com/ongoing-insight/paroxysmal-nocturnal-hemoglobinuria-therapeutics-market-2542

Global Paroxysmal Nocturnal Hemoglobinuria Therapeutics Market: Regional Analysis

North America is expected to dominate in paroxysmal nocturnal hemoglobinuria therapeutics market during the forecast period, owing to new approvals from the FDA. For instance, in 2018, Ravulizumab (Ultomiris) from Alexion Pharmaceuticals and APL2 from Apellis Pharmaceuticals was approved by the FDA, for the treatment of paroxysmal nocturnal hemoglobinuria.

Asia Pacific paroxysmal nocturnal hemoglobinuria therapeutics market size is expected to witness significant growth due to availability of cost-effective treatment and medical tourism for PNH. According to an article published by National Center for Biotechnology Information (NCBI) in 2014, the cost of bone marrow transplant in India was between US$ 10,000 and US$ 40,000 in 2014 and in the U.S., it was between US$ 73,000 and US$ 140,000 in 2012.

Global Paroxysmal Nocturnal Hemoglobinuria Therapeutics Market: Competitive Landscape

Key players operating in the global paroxysmal nocturnal hemoglobinuria therapeutics market include Alexion Pharmaceuticals, Akari therapeutics, Apellis Pharmaceuticals, Amgen Inc, CinnaGen Co, Ra Pharmaceuticals Inc, Alnylam Pharmaceuticals, Achillion Pharmaceuticals Inc, Novartis, Roche, and Regeneron Pharmaceuticals.

Buy-Now this research report: https://www.coherentmarketinsights.com/insight/buy-now/2542

About Coherent Market Insights:            

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

mailto:sales@coherentmarketinsights.com

U.S. Office:

Name:  Mr. Shah

Coherent Market Insights 1001 4th Ave,

# 3200 Seattle, WA 98154, U.S.

US :  +1-206-701-6702

UK :  +44-020-8133-4027

JAPAN :  +050-5539-1737

[anantpandey]

Soliris Drug Market; Analysis on Current Trends 2025

The Soliris Drug market report offers a detailed explanation of different Leading level industries that are functioning in global regions. The Soliris Drug market was developed with a primary focus on the competitive sphere, retail, geographical expansion, and market dynamics, including drivers, constraints, and opportunities. In this report, various chapters deliver a logical understanding of the market scenarios with relevant examples. This report also analyzes the global market competition landscape, market drivers and trends, opportunities and challenges, sales channels, distributors, and Porter's Five Forces Analysis.

To Know More Details About This Report, Get Sample @ http://www.acquiremarketresearch.com/sample-request/387046

The objective of this examine is to determine market sizes for various sectors and countries in recent years and predict values for the next eight years. The report is created to integrate the qualitative and quantitative aspects of the industry both in the regions and in the countries participating in the study. In addition, the report also provides detailed information on key aspects, such as the drivers and challenges that will determine future market growth. In addition, the report should also incorporate opportunities in small markets for interested parties to invest together with a detailed analysis of the competitive landscape and product offerings of key stakeholders.

Major Market Players Covered In This Report:

Alexion

Feel Free To Make an Enquiry Or Customization of This Report @ http://www.acquiremarketresearch.com/enquire-before/387046

The specified segments and sub-sections of the market are explained below:

By Product Type:

Plasma Exchange, Plasma Infusion

By Application/End-user:

PNH, aHUS

By country/region:

North America (United States, Canada, and Mexico)

Europe (Germany, France, UK, Russia, and Italy)

Asia-Pacific (China, Japan, Korea, India, and Southeast Asia)

South America (Brazil, Argentina, Colombia etc.)

Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, and South Africa)

Order This Report Now @ http://www.acquiremarketresearch.com/buy-now/387046

Reasons to Purchase this Report:

Trend estimates in the development of the 2020-2025 Soliris Drug market with recent trends and SWOT analysis

The Scenario of market dynamics, along with opportunities for market growth in the coming years.

Regional and national analysis that combines demand and supply forces that influence market growth.

Market segmentation analysis, including qualitative and quantitative research that includes the impact of economic and political aspects.

A competitive landscape that includes the market share of key players, along with new projects and strategies adopted by players in the last five years.

[oncologyadvice]

eculizumab price

Soliris is used for the treatment of Blood Cancer and is manufactured by Alexion Pharmaceuticals. Strength of this medicine is 300mg. Composition of this medicine is Eculizumab.

Know more about Soliris Injection

Composition: Eculizumab

Manufacturer: Alexion Pharmaceuticals

Indication: Blood cancer

Packaging: Vial

Dosage Form: Injection

If you are looking for eculizumab price, then please visit Magicine Pharma. This medicine is available in Pakistan, Philippines, Egypt, India, Australia and UAE.

[expertofmarketinsights-blog]

Paroxysmal Nocturnal Hemoglobinuria Therapeutics Market: Competitive Intelligence and Tracking Report 2018 – 2026

The paroxysmal nocturnal hemoglobinuria (PNH) is a rare, acquired bone marrow failure disorder, which leads to premature death and impaired red blood cells (RBCs). PNH is characterized by hemolytic anemia, thrombosis, and peripheral blood cytopenia. Mutation in the PIGA-A gene of hematopoietic stem cells causes deficiency of the two glycosylphosphatidylinositol (GPI) anchored proteins, namely CD55 and CD59 in the patient’s body, which gives rise to the premature destruction of RBCs. Click To Read More On Paroxysmal Nocturnal Hemoglobinuria Therapeutics Market

Symptoms of paroxysmal nocturnal hemoglobinuria includes hemolytic anemia, hemoglobinuria, fatigue, breathlessness, abdominal pain, difficulty in controlling bleeding even from very minor wounds, appearance of small red dots on the skin that indicates bleeding under the skin, severe headache, and blood clots (thrombosis). Bone marrow transplant (stem cell transplant) is the only curative therapy for paroxysmal nocturnal hemoglobinuria available so far.

Global Paroxysmal Nocturnal Hemoglobinuria Therapeutics Market: Drivers

The global paroxysmal nocturnal hemoglobinuria therapeutics market size is expected to witness significant growth over the forecast period, owing to increasing demand for PNH therapeutics and rising number of treatment approvals from the U.S. Food and Drug Administration (FDA) for PNH, which includes iron supplements, blood transfusion, blood thinner, Eculizumab (Soliris), and bone marrow transplant. According to a study published in Blood Journal in 2012, the 5 year survival-rate of patients treated with Soliris is 95.5%.

Moreover, new R&D studies are being conducted for development of cost-effective PNH treatment, which is expected to drive the paroxysmal nocturnal hemoglobinuria therapeutics market revenue. For instance, in 2014, the research team of Perelman School of Medicine at Pennsylvania, U.S. investigated a compound named PEG-Cp40, which is long-acting and cost-effective for the treatment of paroxysmal nocturnal hemoglobinuria.

Global Paroxysmal Nocturnal Hemoglobinuria Therapeutics Market: Restraints

The paroxysmal nocturnal hemoglobinuria therapeutics market revenue is expected to hamper because of high cost for the treatment of paroxysmal nocturnal hemoglobinuria. For instance, in 2017, the American Council on Science and Health (ACSH) declared Eculizumab (Soliris) as the most expensive drug in the U.S. and cost of Solirirs ranges up to US$ 500,000 per person per year.

Moreover, the side effects shown by the drug Soliris such as headache, fatigue, nausea, vomiting, diarrhea, muscle pain, and nasal congestion can also negatively impact the paroxysmal nocturnal hemoglobinuria therapeutics market size. There are some serious side effects also, which includes low White Blood Cell (WBC) count, increased chances of bacterial infections such as meningitis, and bacterial sinusitis. According to the Centers for Disease Control and Prevention (CDC) reports of 2017, patients under the therapy of Eculizumab (Soliris) are at 1,000 to 2,000 times greater at risk of getting meningococcal diseases han the healthy individuals in the U.S.

Ask For Sample Copy Of This Business Research Report : https://www.coherentmarketinsights.com/insight/request-sample/2542

Global Paroxysmal Nocturnal Hemoglobinuria Therapeutics Market: Competitive Landscape

Key players operating in the global paroxysmal nocturnal hemoglobinuria therapeutics market include Alexion Pharmaceuticals, Akari therapeutics, Apellis Pharmaceuticals, Amgen Inc, CinnaGen Co, Ra Pharmaceuticals Inc, Alnylam Pharmaceuticals, Achillion Pharmaceuticals Inc, Novartis, Roche, and Regeneron Pharmaceuticals.

Global Paroxysmal Nocturnal Hemoglobinuria Therapeutics Market: Regional Analysis

North America is expected to dominate in paroxysmal nocturnal hemoglobinuria therapeutics market during the forecast period, owing to new approvals from the FDA. For instance, in 2018, Ravulizumab (Ultomiris) from Alexion Pharmaceuticals and APL2 from Apellis Pharmaceuticals was approved by the FDA, for the treatment of paroxysmal nocturnal hemoglobinuria.

Asia Pacific paroxysmal nocturnal hemoglobinuria therapeutics market size is expected to witness significant growth due to availability of cost-effective treatment and medical tourism for PNH. According to an article published by National Center for Biotechnology Information (NCBI) in 2014, the cost of bone marrow transplant in India was between US$ 10,000 and US$ 40,000 in 2014 and in the U.S., it was between US$ 73,000 and US$ 140,000 in 2012.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah Coherent Market Insights 1001 4th Ave, #3200 Seattle, WA 98154 Tel: +1-206-701-6702 Email: sales@coherentmarketinsights.com

[estimize]

5 Stocks to Watch that Report Earnings Tomorrow

Arista Networks (ANET): Arista Networks roared through 2016 only to hit a massive snag at the start of the new year. In late January, the CBP revoked an earlier court ruling over an ongoing patent infringement case between Arista and Cisco. Shares subsequently took a sharp dive but since recovered most of the losses. For the most part, analysts expect the company to continue its trend higher in the fourth quarter, with forecasts for a 30% jump on the top line and 5% on the bottom. A 5% increase in earnings would mark the first quarter since the company went public that earnings failed to reach double digit growth. From a product standpoint Arista continues to find support from cloud networking ports and switches, which topped nearly 10 million cumulative shipments in the third quarter.

What are you expecting for ANET? Get your estimate in here!

MGM Resorts (MGM): Shares of MGM soared 61% in 2016 largely on the back of improving travel trends in key markets such as Las Vegas. Improving employment rates and increasing tourism numbers in the region helped MGM record strong occupancy rates and RevPAR, thereby supporting top line growth. That said, ongoing volatility in Macau over the past few quarters wound up offsetting some of the gains at other resorts. Analyst’s believe a revival is underway in Macau and will boost performance in the quarter to be reported. But Las Vegas Sands weak fourth quarter results at the end of January suggests otherwise. The success of tomorrow’s report hinges on whether travel to Macau improved or simply stayed the same during the fourth quarter.

What are you expecting for MGM? Get your estimate in here!

Alexion Pharmaceuticals (ALXN): Biotech companies are some of the biggest crapshoots of earnings season, with Alexion being no different. Top line growth exceeded double digits for 6 consecutive quarters but that couldn’t help investors who experienced an 8% decline in share value over the past 12 months. Alexion’s two main drugs, Soliris and Strensiq continues to gain traction in core territories including U.S., European and Japanese markets on the back of an increasing patient population. Its newest drug, Kanuma, showed progress throughout its early stage launch in U.S. and German markets. Investors will be keen on management's comments of the Trump administration’s hardened stance on the industry and its potential impact on future performance.

What are you expecting for ALXN? Get your estimate in here!

Wendy’s (WEN): Analysts are asking “Where’s the Growth” after Wendy’s posted 3 consecutive quarters of double digit losses and nearly 8 quarters of negative sales growth. And yet the stock soared 50% in the past 12 months due to a string of positive same store sales growth, ongoing efforts to overhaul the menu, and an emphasis on value offerings like the 4 for 4 deal. A large portion of the overall revenue declines come amid a system wide optimization effort intended to reduce the number of company operated restaurants. Furthermore soft consumer spending and a broad shift away from greasy burgers puts greater pressure on financial performance and may hurt traffic trends.

What are you expecting for WEN? Get your estimate in here!

Hyatt Hotels (H): Hyatt stands to build on the success of the past 3 quarters owing to  increased demand in U.S. markets and improving travel trends. Revenue per available room (RevPAR), hotel operators key performance metric, grew 3.8% in domestic markets and 2.5% systemwide during the third quarter. The company continues to open new hotels in its broader goal of expanding to global markets like China and India. In Q3, the company opened 11 locations and intends to tack on 20 more in the quarter to be reported. Nonetheless, increasing competition, macroeconomic turmoil and consumer’s preference for value channels puts pressure on performance, namely margins.

What are you expecting for H? Get your estimate in here!

Click Here to Estimate

[rishabh3210blog]

Global Myasthenia Gravis Treatment Market Size, Growth & Industry Report to 2026

The global myasthenia gravis treatment market is anticipated to showcase considerable growth during the forecast period (2020-2026). The rising FDA approvals, advancement in new treatment therapies, new product launches, and improvement in surgical procedures are some of the key factors contributing to the growth of the global myasthenia gravis treatment market. Myasthenia gravis is a chronic autoimmune, neuromuscular disorder that leads to weakness in the skeletal muscles. Eyes, face, and swallowing are the most affected muscles. According to the National Center for Biotechnology Information (NCBI), 0.25 and 20 per 1,000,000 population have an annual incidence of myasthenia gravis.

Get Free Sample Copy @ https://www.omrglobal.com/request-sample/myasthenia-gravis-treatment-market

LEO Pharma A/S, Mylan N.V., Bausch Health Companies Inc., Bayer HealthCare AG, Encore Dermatology, Inc., Abbvie Inc., Allergan PLC, Bausch Health Companies Inc., Encore Dermatology Inc., GlaxoSmithKline PLC, Nestle SA, Novartis International AG, Pfizer Inc., and so on are among the key players operating in the global myasthenia gravis treatment market. Mergers and acquisitions, partnerships, collaboration, and strategic agreements among others are the key growth strategies that are being adopted by the major players operating in the market to remain competitive in the market place. Hefty investment in the R&D of new drugs for new product launches is the key strategy adopted by the key players of the global myasthenia gravis treatment market to sustain in the marketplace.

A Full Report of Global Myasthenia Gravis Treatment Market is Available at: https://www.omrglobal.com/industry-reports/myasthenia-gravis-treatment-market

In November 2019, Amneal Pharmaceuticals, Inc. had signed a licensing agreement with Kashiv BioSciences LLC for the development and commercialization of K127 in the US. K127 is an extended-release tablet of pyridostigmine, for the treatment of myasthenia gravis which is used to offer rapid onset and 24-hour coverage for improved symptom control, better tolerability, better compliance, and quality of life to the myasthenia gravis patients. The commercialization of the product is anticipated to drive the growth of the myasthenia gravis treatment market in the US.  

In March 2019, Novartis AG had received FDA approval for Mayzent (siponimod) tablets, the first oral drug to treat the secondary progressive autoimmune disorder. In October 2017, Alexion Pharmaceuticals, Inc. had received the US FDA approval for Soliris (eculizumab) as a treatment for adult patients with generalized myasthenia gravis and are anti-acetylcholine receptor (AchR) antibody-positive. In Phase 3 REGAIN trial and its continuing open-label extension trial, Soliris showed therapeutic advantages for patients with anti-AchR antibody-positive who had previously failed immunosuppressive care and continued to experience severe symptoms of the unresolved disease, which could include problems seeing, walking, communicating, chewing, and respiratory.

Global Myasthenia Gravis Treatment Market Segmentation

By Treatment

Medication

o          Cholinesterase Inhibitors

o          Corticosteroids

o          Immunosuppressants

Surgery

Others

By End-User

Hospitals

Clinics

Other

Global Myasthenia Gravis Treatment Market – Segment by Region

North America

United States

Canada

Europe

UK

Germany

Italy

Spain

France

Rest of Europe

Asia-Pacific

China

Japan

India

Rest of the Asia-Pacific

Rest of the World

For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/myasthenia-gravis-treatment-market

About Orion Market Research

Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.

Media Contact: Company Name: Orion Market Research Contact Person: Mr. Anurag Tiwari Email: info@omrglobal.com Contact no: +91 780-304-0404

[digitallyunpluggedmagazine]

Global Soliris Drug Market 2019 Industry Analysis, Share, Growth, Sales, Trends, Supply, Forecast 2025

Global Soliris Drug Market 2019 Industry Analysis, Share, Growth, Sales, Trends, Supply, Forecast 2025

WiseGuyReports.com adds “Global Soliris Drug Market Professional Survey Report 2019” reports to its database.

PUNE, MAHARASHTRA, INDIA, December 19, 2019 /EINPresswire.com/ — Soliris Drug Market:

Executive Summary

In developed as well as developing countries, medicines are available after branding. The medicines that are available in brand names are also circulated as generic medicines. The…

[smithrose18-blog]

The report “Global PNH and aHUS Market: Industry Analysis & Outlook (2017-2021)” provides an extensive research and detailed analysis of the present market along with future outlook.

Complete report on Global PNH & aHUS Market spread across 69 pages with providing 4 company profiles, 6 tables and 33 charts is now available at http://www.marketreportsonline.com/688972.html.

The report discusses the major growth drivers and challenges of the market, covering the U.S., Europe and Asia-Pacific region along with the global market. The report profiles the key players of the market including Alexion Pharmaceuticals Inc., Alnylam Pharmaceuticals Inc, Omeros Corporation and RA Pharmaceuticals.

PNH and aHUS, both are extremely rare and genetic diseases. Due to PNH, destruction of red blood cells of a person occurs quite sooner than it should. It is an acquired hematopoietic stem cell disorder. Hematopoietic stem cells are developed in bone marrow and eventually turn into red blood cells, white blood cells and platelets. A person with PNH has some defected hematopoietic cells which create defective red blood cells. These defective cells are highly susceptible to premature destruction by the complement system. aHUS is a disorders in which blood clots are formed in small blood vessels throughout the body. TMA can lead to heart stroke, attack, kidney failure and death. Soliris is the only drug treatment available in the market for treating these diseases.

Regionally, Europe held the largest share in the global PNH drug market and the U.S. dominated the global aHUS drug market, supported by favorable reimbursement policies In terms of patient population, Asia-pacific region had the highest number of PNH and aHUS patients. With the increasing technological advancements in diagnosis techniques of PNH and aHUS, the number of diagnosed patients is likely to grow globally.

Purchase a copy of this “Global PNH & aHUS Market” research report at USD 800 (Single User License) http://www.marketreportsonline.com/contacts/purchase.php?name=688972.

The global PNH and aHUS market is expected to grow in future due to prolonged orphan drug market exclusivity, attractive orphan drug policies, increasing pharmaceutical R&D expenditure, rising health care expenditure. Key trends of this market include progressing drugs under pipeline, increasing prevalence of blood and bone marrow related disorders and favorable reimbursement policies. However, there are some factors which can hinder the market growth including high costs of drugs and associated risks.

Browse all latest pharmaceuticals market research reports at http://www.marketreportsonline.com/cat/pharmaceuticals-market-research.html.

About Us: Market Reports Online is a comprehensive online library of more than 100,000 reports, in-depth market research studies on thousands of micro markets and a range of industries. The reports are analytically and statistically rich, and offer a comprehensive view of the dynamic market scenario across the globe. We offer online and offline support services to ensure your research requirements are met on time.

Contact Us: Hrishikesh Patwardhan 2nd Floor, Metropole, Next to Inox Theatre, Bund Garden Road, Pune - 411001. Maharashtra, India. Tel: + 1 888 391 5441 E-mail: sales@marketreportsonline.com

[calvinzeepeda79]

5 Stocks to Watch that Report Earnings Tomorrow

Arista Networks (ANET): Arista Networks roared through 2016 only to hit a massive snag at the start of the new year. In late January, the CBP revoked an earlier court ruling over an ongoing patent infringement case between Arista and Cisco. Shares subsequently took a sharp dive but since recovered most of the losses. For the most part, analysts expect the company to continue its trend higher in the fourth quarter, with forecasts for a 30% jump on the top line and 5% on the bottom. A 5% increase in earnings would mark the first quarter since the company went public that earnings failed to reach double digit growth. From a product standpoint Arista continues to find support from cloud networking ports and switches, which topped nearly 10 million cumulative shipments in the third quarter.

What are you expecting for ANET? Get your estimate in here!

MGM Resorts (MGM): Shares of MGM soared 61% in 2016 largely on the back of improving travel trends in key markets such as Las Vegas. Improving employment rates and increasing tourism numbers in the region helped MGM record strong occupancy rates and RevPAR, thereby supporting top line growth. That said, ongoing volatility in Macau over the past few quarters wound up offsetting some of the gains at other resorts. Analyst’s believe a revival is underway in Macau and will boost performance in the quarter to be reported. But Las Vegas Sands weak fourth quarter results at the end of January suggests otherwise. The success of tomorrow’s report hinges on whether travel to Macau improved or simply stayed the same during the fourth quarter.

What are you expecting for MGM? Get your estimate in here!

Alexion Pharmaceuticals (ALXN): Biotech companies are some of the biggest crapshoots of earnings season, with Alexion being no different. Top line growth exceeded double digits for 6 consecutive quarters but that couldn’t help investors who experienced an 8% decline in share value over the past 12 months. Alexion’s two main drugs, Soliris and Strensiq continues to gain traction in core territories including U.S., European and Japanese markets on the back of an increasing patient population. Its newest drug, Kanuma, showed progress throughout its early stage launch in U.S. and German markets. Investors will be keen on management’s comments of the Trump administration’s hardened stance on the industry and its potential impact on future performance.

What are you expecting for ALXN? Get your estimate in here!

Wendy’s (WEN): Analysts are asking “Where’s the Growth” after Wendy’s posted 3 consecutive quarters of double digit losses and nearly 8 quarters of negative sales growth. And yet the stock soared 50% in the past 12 months due to a string of positive same store sales growth, ongoing efforts to overhaul the menu, and an emphasis on value offerings like the 4 for 4 deal. A large portion of the overall revenue declines come amid a system wide optimization effort intended to reduce the number of company operated restaurants. Furthermore soft consumer spending and a broad shift away from greasy burgers puts greater pressure on financial performance and may hurt traffic trends.

What are you expecting for WEN? Get your estimate in here!

Hyatt Hotels (H): Hyatt stands to build on the success of the past 3 quarters owing to  increased demand in U.S. markets and improving travel trends. Revenue per available room (RevPAR), hotel operators key performance metric, grew 3.8% in domestic markets and 2.5% systemwide during the third quarter. The company continues to open new hotels in its broader goal of expanding to global markets like China and India. In Q3, the company opened 11 locations and intends to tack on 20 more in the quarter to be reported. Nonetheless, increasing competition, macroeconomic turmoil and consumer’s preference for value channels puts pressure on performance, namely margins.

What are you expecting for H? Get your estimate in here!

Click Here to Estimate

from Tumblr http://ift.tt/2lT9tsn